PDT Partners’s Clearside Biomedical CLSD Stock Holding History

PDT Partners’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-708	Closed	-$29K	–	960
2021 Q4	$29K	Buy	+708	New	+$45.9K	﹤0.01%	851
2017 Q2	–	Sell	-4,487	Closed	-$534K	–	524
2017 Q1	$534K	Buy	+4,487	New	+$530K	0.03%	370

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's CLSD Position: Q1 2022 in Review

PDT Partners sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 708 shares — an estimated $29K sold.

PDT Partners first reported a position in CLSD in Q1 2017 and held it in 2 quarters. The position peaked at $534K in Q1 2017. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

PDT Partners reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
PDT Partners sold 708 Clearside Biomedical shares in Q1 2022, an estimated $29K.
PDT Partners first reported a position in Clearside Biomedical in Q1 2017 and held it in 2 quarters.
PDT Partners's Clearside Biomedical position peaked at $534K in Q1 2017.
60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on PDT Partners's 13F filing for Q1 2022, filed 16 May 2022.